Autism Clinical Risk Factors Investigation With Microbiome and Metabolome Profiling

Sponsor
October University for Modern Sciences and Arts (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05849233
Collaborator
Ain Shams University (Other)
100
1
12
8.3

Study Details

Study Description

Brief Summary

The role of gut microbiome was recently raised in the pathogenesis of neurodevelopmental disorders including autism spectrum disorder (ASD). In view of these evidences, together with poor conductance of researches on gut microbiota in ASD patients in Egypt, in addition to the absence of definite medical test or biological marker for diagnosis of ASD, the present study is designed to study clinical risk factor of autism and the predominant gut microbiome in autistic children in an attempt to identify gut bacteria which are likely related to ASD and to correlate these bacteria and clinical variables with the severity of autism. Interestingly, the totality of the studies focusing on the fecal metabolome features in ASD has investigated the differences between subjects with and without this disorder, while ignoring potential correlations between microbiome, metabolome and ASD severity

Condition or Disease Intervention/Treatment Phase
  • Other: no intervention

Detailed Description

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by impairment in communication and social interaction, and repetitive behaviors. 1%-1.5% of children in developed nations has ASD, This rate is said to range between 0.15% and 0.8% in low- and middle-income countries. Over the past decades, the prevalence of ASD has increased worldwide. Scientists have been trying to explore the molecular mechanisms behind the pathology of ASD. Several evidence suggests that genetic factors such as chromosomal abnormalities and environmental factors like diet and stress are involved in the pathogenesis and advancement of ASD. Accumulating research has demonstrated the gut-brain axis or multiple biochemical signaling pathways that take place between the gastrointestinal tract (GI tract) and the central nervous system (CNS), and its possible association with ASD. Mounting evidence explains that gut microbial dysbiosis is implicated in the pathogenesis of multiple diseases, including inflammatory bowel disease (IBS), coeliac disease (CD), and ASD. A Recent Egyptian study showed that an evidence of changes in the gut microbiome of ASD children compared to the unrelated controls. However, the microbiome profile of siblings was more like that of autistic children than that of unrelated controls. These observations may highlight the importance of the interplay between environmental and host genetic factors in shaping the gut microbiome. The study also emphasized the importance of identification of microbiome and specific microorganisms' changes that can be targeted for diagnosis as well as for treatment of ASD. This study aims to investigate clinical risk factors of autism and to elucidate the changes in gut microbiome in Egyptian autistic children and their possible correlation with clinical outcomes and the severity of the disease.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Investigating Autism Clinical Risk Factors With Profiling the Intestinal Microbiome and Metabolome Analysis and Their Impact on Disease Severity and Clinical Outcomes in Autistic Egyptian Children
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Autism clinical risk factors [1 year]

    prenatal, Natal and postnatal history then regression analysis

Secondary Outcome Measures

  1. Intestinal microbiome [1 year]

    Stool Sample collection then intestinal microbiome investigation

  2. metabolome Analysis [1 year]

    fecal metabolome analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 9 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  1. Autistic children aged between 3-9 years based on DSM V
Exclusion criteria:
  1. Past or present history of seizures or any other neurological illness

  2. Past or present history of any psychiatric illness Those patient will be excluded to avoid confounders because those diseases also affected by microbiome The inclusion and exclusion criteria will be determined by the medical history taken from the parents of the children before test application.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ain shams University Hospitals (Unit of Phoniatrics-Otorhinolaryngology department ) Cairo Egypt

Sponsors and Collaborators

  • October University for Modern Sciences and Arts
  • Ain Shams University

Investigators

  • Principal Investigator: sara Eladawy, PhD, MSa university
  • Study Director: amira Abdeldaim, PhD, MSA university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
October University for Modern Sciences and Arts
ClinicalTrials.gov Identifier:
NCT05849233
Other Study ID Numbers:
  • RSPL 1.6
First Posted:
May 8, 2023
Last Update Posted:
May 8, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by October University for Modern Sciences and Arts
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 8, 2023